TOG Review (RCOG Journal)
MRCOG Part 2
Maternal Medicine
Multiple sclerosis and pregnancy
Key Statistics
- 20–30% — Relapse in first 3–4 months postpartum
- 285.8 — UK prevalence per 100,000 women
- 85% — Diagnosed with relapsing-remitting MS
Don't-miss facts
-
Postpartum relapse in 20–30% within 3–4 months; best predictor = pre-pregnancy relapse rate
-
Epidural/spinal is safe — no increased relapse risk; use an indwelling catheter with epidural and empty the bladder periodically in labour
-
Acute flare = oral/IV steroids (safe in pregnancy and breastfeeding). MRI safe all trimesters — no gadolinium
-
Steroids >5 mg prednisolone equivalence for >4 weeks pre-delivery → give stress-dose hydrocortisone at delivery to prevent adrenal crisis
-
Neurogenic bladder → monthly MSU; reduced mobility/wheelchair + risk factors → stockings + LMWH
-
FGR risk ~1.7× → third-trimester growth scans. Vaginal delivery safe; caesarean only for severe neurological problems or obstetric indication
-
Breastfeeding contraindicated once DMT restarted; safe on steroids — BNF: feed 4 hours after administration
-
Relatively safe in early pregnancy: glatiramer acetate and interferon-β (neither crosses the placenta). Stopping a DMT risks rebound within 3 months
New relapse vs pseudo-relapse
Relapse: NEW symptom not experienced before (e.g. first episode of optic neuritis) → urgent neurology review
Pseudo-relapse: flare of ALL existing symptoms, sometimes more intense (e.g. worse gait/fatigue)
Abbreviation Key
- MS / RRMS — multiple sclerosis / relapsing remitting MS
- EDSS — expanded disability status scale
Source: Kanagaraj P, Evangelou N, Kapoor D. Multiple sclerosis and pregnancy. The Obstetrician & Gynaecologist 2019;21:177–184. doi:10.1111/tog.12576
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).